ArticleBlood research2022

Immunoglobulin repletion during blinatumomab therapy does not reduce the rate of secondary hypogammaglobulinemia and associated infectious risk.

Stephanie Wo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.